Clofazimine therapy for lepromatous leprosy: A historical perspective

International Journal of Dermatology

Volumn 38, Issue 1, 1999, Pages 70-74

  Fajardo Jr , Tranquilino T ^b   Abalos, Rodolfo M ^b   Dela Cruz, Eduardo C ^b   Villahermosa, Laarni G ^b   Walsh, Douglas S ^a   Cellona, Roland V ^b   Balagon, Maria V ^b   Tan, Esterlina V ^b   Walsh, Gerald P ^b  

^a APACHE POINT OBSERVATORY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLOFAZIMINE; DAPSONE; RIFAMPICIN; STREPTOMYCIN;

DRUG EFFICACY; HISTORY; HUMAN; HYPERPIGMENTATION; ICHTHYOSIS; INTRAMUSCULAR DRUG ADMINISTRATION; LEPROMATOUS LEPROSY; MYCOBACTERIUM LEPRAE; ORAL DRUG ADMINISTRATION; REVIEW; SKIN BIOPSY; SKIN TOXICITY;

ADULT; CLOFAZIMINE; HISTORY, 20TH CENTURY; HUMANS; LEPROSTATIC AGENTS; LEPROSY, LEPROMATOUS; MALE; MYCOBACTERIUM LEPRAE; PHILIPPINES; SKIN;

EID: 13044268456     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-4362.1999.00610.x     Document Type: Review

References (28)

1. Browne SG, Hogerzeil LM. "B663" in the treatment of leprosy: preliminary report of a pilot trial. Lepr Rev 1961; 33: 6-10.
2. Arbiser JL, Moschella SL. Clofazimine: a review of its medical uses and mechanisms of action. J. Am Acad Dermatol 1995; 32: 241-247.
3. Madrid, Report of the Committee on Classification, International Congress of Leprosy. Int J Lepr 1953; 34: 255-273.
4. Cochrane RG, Davey TF. Leprosy in Theory and Practice, 2nd edn. Bristol: John Wright, 1964.
5. Sehgal VN, Jain MK, Srivastava G. Evolution of the classification of leprosy. Int J. Dermatol 1989; 28: 161-167.
6. Ridley DS, Jopling WH. Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobact Dis 1966; 34: 255-273.
7. Tolentino JG, Rodriquez JN, Abalos RM. Controlled drug trial of B.663 compared with DDS. Preliminary (48 week) report. Int. J Lepr Other Mycobact Dis 1971; 39: 738-741.
8. Bryceson A. Pfaltzgraf RE. Leprosy, 3rd edn. New York: Churchill Livingstone, 1990.
9. Fajardo TT. Abalos RM. Clofazamine (B663, Lamprene) monotherapy of dapsone-resistant leprosy (Abstract). Int J Lepr 1984; 52: 710.
10. Waters MF. The diagnosis and management of dapsone-resistant leprosy. Lepr Rev 1977; 48: 95-105.
11. Chang YT. Story behind the clinical trial of B.663 in leprosy. Int J Lepr 1967; 35 78-80.
12. Yawalkar SJ, Vischer W. Lamprene (clofazimine) in leprosy. Basic information. Lepr Rev 1979; 50: 135-144.
13. Walsh DS, Guido LS, Fajardo TT. The treatment of leprosy: a brief history and current chemotherapeutic guidelines. Med Sci Res 1989; 194: 271-273.
14. Garrelts JC. Clofazimine: a review of its use in leprosy and Mycobacterium avium complex infection. Ann Pharmacother 1991; 25: 525-531.
15. Mehta RT. Liposome encapsulation of clofazimine reduces toxicity in vitro and in vivo and improves therapeutic efficacy in the beige mouse model of sisseminated Mycobacterium avium-M. intracellulare complex infection. Antimicrob Agents Chemother 1996; 40: 1893-1902.
16. Sehgal VN, Srivastava G. Histoid leprosy: a prospective diagnostic study in 38 patients. Dermatologica 1988; 177: 212-217.
17. Jamet P, Traore I, Husser JA, Ji B. Short-term trial of clofazimine in previously untreated lepromatous leprosy. Int J Lepr Other Mycobact Dis 1992; 60: 542-548.
18. Levy L. Clofazimine-resistant M. leprae. Int J Lepr Other Mycobact Dis 1986; 54: 137-140.
19. Morrison NE, Marley GM. Clofazimine binding studies with deoxyribonucleic acid Int J Lepr Other Mycobact Dis 1976; 44: 475-481.
20. Morrison NE, Marley GM. The mode of action of clofazimine DNA binding studies. Int J Lepr Other Mycobact Dis 1976; 44: 133-134.
21. Van Rensburg CE, Joone GK, JF OS, Anderson R. Antimicrobial activities of clofazimine and B669 are mediated by lysophospholipids. Antimicrob Agents Chemother 1992; 36: 2729-2735.
22. 125I-labelled immune complexes by clofazimine treated macrophage cultures. Clin Exp Immunol 1982; 48: 268-272.
23. Ramasesh N, Krahenbuhl JL, Hastings RC. In vitro effects of antimicrobial agents on Mycobacterium leprae in mouse peritoneal macrophages. Antimicrob Agents Chemother 1989; 33: 657-662.
24. Hastings RC, Gillis TP, Krahenbuhl JL, Franzblau SG. Leprosy. Clin Microbiol Rev 1988; 1: 330-348.
25. van Zyl JM, Bhasson K, Kriegler A, van der Walt BJ. Mechanisms by which clofazimine and dapsone inhibit the myeloperoxidase system. A possible correlation with their anti-inflammatory properties. Biochem Pharmacol 1991; 42: 599-608.
26. van Rensburg CE, Gatner EM, Imkamp FM, Anderson R. Effects of clofazimine alone or combined with dapsone on neutrophil and lymphocyte functions in normal individuals and patients with lepromatous leprosy. Antimicrob Agents Chemother 1982; 21: 693-697.
27. Kansal RG, Gomez-Flores R, Sinha I, Mehta RT. Therapeutic effect of liposomal clofazimine against Mycobacterium avium complex in mice depends on size of initial inoculum and duration of infection. Antimicrob Agents Chemother 1977; 41: 17-23.
28. Gomex-Flores R, Tucker SD, Kansal RG, et al. Enhancement of antibacterial activity of clofazimine against Mycobacterium avium-Mycobacterium intracellulare complex infection induced by IFN-γ is mediated by TNF-α. J. Antimicrob Chemother 1977; 39: 189-197.